Anti-Biofilm Agents to Overcome <i>Pseudomonas aeruginosa</i> Antibiotic Resistance
<i>Pseudomonas aeruginosa</i> is one of world’s most threatening bacteria. In addition to the emerging prevalence of multi-drug resistant (MDR) strains, the bacterium also possesses a wide variety of virulence traits that worsen the course of the infections. Particularly, its ability to...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/1/92 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587691909185536 |
|---|---|
| author | Marie Hanot Elodie Lohou Pascal Sonnet |
| author_facet | Marie Hanot Elodie Lohou Pascal Sonnet |
| author_sort | Marie Hanot |
| collection | DOAJ |
| description | <i>Pseudomonas aeruginosa</i> is one of world’s most threatening bacteria. In addition to the emerging prevalence of multi-drug resistant (MDR) strains, the bacterium also possesses a wide variety of virulence traits that worsen the course of the infections. Particularly, its ability to form biofilms that protect colonies from antimicrobial agents is a major cause of chronic and hard-to-treat infections in immune-compromised patients. This protective barrier also ensures cell growth on abiotic surfaces and thus enables bacterial survival on medical devices. Hence, as the WHO alerted to the need to develop new treatments, the use of anti-biofilm agents (ABAs) appeared as a promising approach. Given the selection pressure imposed by conventional antibiotics, a new therapeutic strategy has emerged that aims at reducing bacterial virulence without inhibiting cell growth. So-called anti-virulence agents (AVAs) would then restore the efficacy of conventional antibiotics (ATBs) or potentiate the effectiveness of the immune system. The last decade has seen the development of ABAs as AVAs against <i>P. aeruginosa</i>. This review aims to highlight the design strategy and critical features of these molecules to pave the way for further discoveries of highly potent compounds. |
| format | Article |
| id | doaj-art-13e943a6506b4f1daa85ebbbdb6c9966 |
| institution | Kabale University |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-13e943a6506b4f1daa85ebbbdb6c99662025-01-24T13:45:21ZengMDPI AGPharmaceuticals1424-82472025-01-011819210.3390/ph18010092Anti-Biofilm Agents to Overcome <i>Pseudomonas aeruginosa</i> Antibiotic ResistanceMarie Hanot0Elodie Lohou1Pascal Sonnet2AGIR, UR 4294, Faculté de Pharmacie, Université de Picardie Jules Verne, 1 Rue des Louvels, 80000 Amiens, FranceAGIR, UR 4294, Faculté de Pharmacie, Université de Picardie Jules Verne, 1 Rue des Louvels, 80000 Amiens, FranceAGIR, UR 4294, Faculté de Pharmacie, Université de Picardie Jules Verne, 1 Rue des Louvels, 80000 Amiens, France<i>Pseudomonas aeruginosa</i> is one of world’s most threatening bacteria. In addition to the emerging prevalence of multi-drug resistant (MDR) strains, the bacterium also possesses a wide variety of virulence traits that worsen the course of the infections. Particularly, its ability to form biofilms that protect colonies from antimicrobial agents is a major cause of chronic and hard-to-treat infections in immune-compromised patients. This protective barrier also ensures cell growth on abiotic surfaces and thus enables bacterial survival on medical devices. Hence, as the WHO alerted to the need to develop new treatments, the use of anti-biofilm agents (ABAs) appeared as a promising approach. Given the selection pressure imposed by conventional antibiotics, a new therapeutic strategy has emerged that aims at reducing bacterial virulence without inhibiting cell growth. So-called anti-virulence agents (AVAs) would then restore the efficacy of conventional antibiotics (ATBs) or potentiate the effectiveness of the immune system. The last decade has seen the development of ABAs as AVAs against <i>P. aeruginosa</i>. This review aims to highlight the design strategy and critical features of these molecules to pave the way for further discoveries of highly potent compounds.https://www.mdpi.com/1424-8247/18/1/92biofilmbacterial virulence<i>Pseudomonas aeruginosa</i>drug designanti-biofilm agents |
| spellingShingle | Marie Hanot Elodie Lohou Pascal Sonnet Anti-Biofilm Agents to Overcome <i>Pseudomonas aeruginosa</i> Antibiotic Resistance Pharmaceuticals biofilm bacterial virulence <i>Pseudomonas aeruginosa</i> drug design anti-biofilm agents |
| title | Anti-Biofilm Agents to Overcome <i>Pseudomonas aeruginosa</i> Antibiotic Resistance |
| title_full | Anti-Biofilm Agents to Overcome <i>Pseudomonas aeruginosa</i> Antibiotic Resistance |
| title_fullStr | Anti-Biofilm Agents to Overcome <i>Pseudomonas aeruginosa</i> Antibiotic Resistance |
| title_full_unstemmed | Anti-Biofilm Agents to Overcome <i>Pseudomonas aeruginosa</i> Antibiotic Resistance |
| title_short | Anti-Biofilm Agents to Overcome <i>Pseudomonas aeruginosa</i> Antibiotic Resistance |
| title_sort | anti biofilm agents to overcome i pseudomonas aeruginosa i antibiotic resistance |
| topic | biofilm bacterial virulence <i>Pseudomonas aeruginosa</i> drug design anti-biofilm agents |
| url | https://www.mdpi.com/1424-8247/18/1/92 |
| work_keys_str_mv | AT mariehanot antibiofilmagentstoovercomeipseudomonasaeruginosaiantibioticresistance AT elodielohou antibiofilmagentstoovercomeipseudomonasaeruginosaiantibioticresistance AT pascalsonnet antibiofilmagentstoovercomeipseudomonasaeruginosaiantibioticresistance |